Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction  by Smart, Steven C et al.
Dobutamine-Atropine Stress
Echocardiography for Risk Stratification in
Patients with Chronic Left Ventricular Dysfunction
Steven C. Smart, MD, FACC, Peter N. Dionisopoulos, MD, Thomas A. Knickelbine, MD,
Timothy Schuchard, MD, Kiran B. Sagar, MD, FACC
Milwaukee, Wisconsin
OBJECTIVE To assess the prognostic value of sustained improvement, scar and inducible ischemia with or
without viability in patients with chronic left ventricular dysfunction (LVD).
BACKGROUND Dobutamine-atropine stress echocardiography (DASE) accurately detects scar, reversible
dysfunction and the extent of coronary artery disease in LVD.
METHODS Three hundred fifty consecutive patients (age 62 6 13 years, mean 6 SD, 215 men/135
women) with moderate to severe LVD (LVEF , 40%, mean 30 6 8%) underwent DASE
and were followed for $18 months. Dobutamine-atropine stress echocardiographic findings
were classified according to sustained improvement in all vascular territories, scar, inducible
ischemia (worsening wall motion at peak dose only or biphasic responses) and their extent.
RESULTS Sustained improvement occurred in 83 patients (24%), scar alone in 99 (28%) and inducible
ischemia in 168 (48%, with biphasic responses in 104). Ischemia was induced in all vascular
territories in 26 patients. Patients with sustained improvement or scar alone were treated
medically, whereas 46% (78/168) with inducible ischemia were revascularized (coronary
bypass surgery, n 5 67 or angioplasty, n 5 11). There were 76 hard events including cardiac
death in 59, nonfatal myocardial infarction in 11, and resuscitated sudden death in 6. Hard
events were rare in sustained improvement (5%, 4/83), uncommon in scar (13%, 13/99) and
common (p , 0.01) in medically treated patients with inducible ischemia (59%, 53/90).
Cardiac deaths were especially common (p , 0.01) in patients with biphasic responses (55%,
28/51). Inducible ischemia independently predicted hard events (x2 5 75.35, p , 0.001)
along with reduced LVEF at peak dose (x2 5 8.38, p 5 0.004). Hard cardiac events were
uncommon (8%, 6/78, p , 0.001) in patients with inducible ischemia who underwent early
revascularization.
CONCLUSIONS Inducible ischemia during DASE was the major determinant of outcome in LVD and
independent of clinical data and left ventricular function. Improved wall thickening alone and
scar alone predicted good outcome. Survival of patients with inducible ischemia was better
after revascularization. (J Am Coll Cardiol 1999;33:512–21) © 1999 by the American
College of Cardiology
Chronic left ventricular dysfunction (LVD) is a major cause
of morbidity and mortality (1–3). Left ventricular ejection
fraction (LVEF) and age are predictive of outcome, but risk
stratification is optimized by evaluation for coronary artery
disease (CAD) and the mechanism of ventricular dysfunc-
tion (1–7). Nuclear medicine imaging, especially positron
emission tomography (PET), has shown that viable myo-
cardium jeopardized by CAD predicted adverse outcome
and the benefits of revascularization, but it is expensive and
not widely available (8–13).
Dobutamine-atropine stress echocardiography (DASE)
is being increasingly used to evaluate patients with LVD for
myocardial viability and ischemia (14–22) and distinguish
nonischemic from ischemic cardiomyopathies. Inducible
ischemia with or without improvement at low dose (bipha-
sic responses) is specific and sensitive for CAD in these
patients (17,19,21). Biphasic responses are also predictive of
recovery with revascularization (19,20). Akinesis or dyski-
nesis unresponsive to dobutamine is indicative of myocardial
scar (15,19). Sustained improvement in all vascular territo-
ries noninvasively differentiates nonischemic from ischemic
cardiomyopathies (17,22).
The findings of scar, sustained improvement at low and
peak dose and inducible ischemia with or without viability
(biphasic responses) during DASE may also be useful for
predicting outcome in LVD. In the only prior study, both
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improved wall thickening and worsening wall motion pre-
dicted adverse outcome (18). The authors did not differen-
tiate the relative roles of myocardial viability and ischemia in
predicting outcome. These findings correlated with a low
sensitivity (42%) of inducible ischemia for CAD (18).
The aims of the present study were to 1) determine the
value of the findings of scar, sustained improvement, induc-
ible ischemia (worsening at peak dose or biphasic responses)
and their extent in predicting outcome in patients with
LVD, and 2) assess the effect of revascularization of high
risk patients. To investigate these aims, 350 consecutive
patients with LVEFs ,40% underwent DASE and were
followed for $18 months.
METHODS
Patient selection. From December 1992 to December
1996, 350 consecutive patients with LVEFs ,40% without
recent (,3 months) myocardial infarction or critical aortic
stenosis underwent DASE for the detection of CAD or
myocardial viability at the Medical College of Wisconsin,
Milwaukee, Wisconsin. All were .21 years of age and gave
informed consent and were followed for at least eighteen
months.
Dobutamine-atropine stress echocardiography. DASE
was performed with continuous 12 lead ECG monitoring
(23). b adrenergic antagonists were not stopped. The stages
of dobutamine infusion were 5, 10, 20, 30 and 40 mg/kg/
min. Intravenous atropine (0.2 to 0.4 mg every 2 min to a
maximum of 2 mg) was infused to achieve target heart rates
if: 1) heart rate was submaximal at a maximal dose of
dobutamine, or 2) cyclic variability in heart rate .10 bpm,
hyperdynamic wall motion (end systolic left ventricular
diameter ,1 cm), or mild to moderate nausea occurred at
submaximal doses of dobutamine (23). Stage duration was
7.5 min at 5 and 10 mg/kg/min and 5 min thereafter. Blood
pressure was measured at 5 min of each stage.
Endpoints were: maximum dose, heart rate $120 bpm
for patients .65 yr of age and $135 bpm for patients
#65 yr (24), limiting chest pain, headaches, severe nausea,
vomiting, $2 mm of ST elevation or depression compared
to baseline in $2 leads, hypotension (systolic blood pressure
,90 mm Hg), hypertension (systolic blood pressure
$240 mm Hg), ventricular tachycardia ($4 complexes at
cycle lengths ,600 msec) or sustained supraventricular
tachyarrhythmias. Esmolol (0.1 to 0.5 mg/kg IV every
2 min up to 1.5 mg/kg) and nitroglycerin (0.4 mg SL every
5 min up to 3 doses) were administered after stopping the
infusion if chest pain was severe or did not resolve within
4 min (23). The 59 (17%) patients with submaximal heart
rates were grouped with those with maximal rates.
Six echocardiographic views (parasternal long and short
axis and apical 4 chamber, 2 chamber, long axis, and short
axis) were videotaped at rest and each dose of dobutamine
and atropine. Images were digitized on-line at four stages
(rest, 5 mg/kg/min, 10 mg/kg/min peak dose) with a Cine
View (Prizm Imaging, Louisville, Colorado) R-wave trig-
gered acquisition system and stored in a quad screen,
continuous loop format on 3.5-inch floppy discs (23).
Echocardiographic measurements. Left ventricular septal
and posterior wall thickness, diameter and fractional short-
ening were measured in the parasternal long axis view. Left
ventricular volumes and LVEF were measured in the apical
4 chamber view by the modified Simpson’s rule. Intra and
interobserver variability of echocardiographic measurements
were previously assessed in a cohort of 100 patients (25).
Chamber size and wall thickness were reproducible
(#0.1 cm) in 90% of studies. Left ventricular volumes and
LVEF were reproducible (#8%) in 85%.
Dobutamine stress echocardiogram analysis. The dobut-
amine echocardiographic images were interpreted by two
investigators without knowledge of the clinical, angio-
graphic or follow-up data. The videotape recordings were
made available to the interpreters but were not routinely
reviewed. Intraobserver variability was assessed in 50 ran-
domly selected patients.
The left ventricle was evaluated using the previously
described scoring system (1 5 normal, 2 5 hypokinesis, 3 5
akinesis and 4 5 dyskinesis) and standard 16-segment
model (23,26). Segments were assigned to the left anterior
descending, left circumflex and right coronary arterial dis-
tributions according to the vascular distribution of segments
(23). Normal was defined as normal wall thickening. Hy-
pokinesis was defined as reduced wall thickening. Akinesis
was defined as the absence of wall thickening. Dyskinesis
was defined as paradoxical excursion away from the lumen
and systolic wall thinning.
Global wall motion score index was calculated at each
stage. Patients were classified according to three responses
(23). Sustained improvement was defined as a sustained
improvement in multiple dysfunctional segments in all
vascular territories at low (5 and 10 mg/kg/min) and peak
dose. Scar was akinesis or dyskinesis with or without wall
thinning and increased echogenicity in $2 contiguous
segments that did not change at low or peak dose (26–28).
Inducible ischemia was defined as: 1) decreased wall thick-
ening at peak dose after no change at low dose in $2
contiguous segments that were normal or hypokinetic at rest
or 2) a biphasic response (i.e., improved wall thickening in
$2 contiguous dysfunctional segments at low dose with
worsening at peak dose). Akinetic segments that changed to
Abbreviations and Acronyms
BPM 5 beats per minute
CAD 5 coronary artery disease
DASE 5 dobutamine-atropine stress echocardiography
LVD 5 chronic left ventricular dysfunction
LVEF 5 left ventricular ejection fraction
PET 5 positron emission tomography
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dyskinesis or the reverse were considered unchanged (29).
Multiple abnormalities were defined as scar or inducible
ischemia in $2 vascular territories (23). Patients with
combinations of findings were categorized hierarchically
(inducible ischemia . scar . sustained improvement).
Follow-up data/definition of adverse outcome. Patients
were followed by patient interviews, hospital chart reviews
and/or telephone interviews for a minimum of eighteen
months or until a hard event occurred (26). Adverse
outcomes were cardiac death, nonfatal myocardial infarc-
tion, resuscitated sudden death (ventricular tachycardia or
fibrillation), late (.1 month after DASE) myocardial re-
vascularization and congestive heart failure requiring hospi-
talization. Hard events were cardiac death (sudden death or
death related to myocardial infarction, congestive heart
failure or cardiac arrhythmias), nonfatal myocardial infarc-
tion (hospital admission for chest pain lasting .20 min,
EKG changes and elevated creatine kinase or lactate dehy-
drogenase isoenzymes) and resuscitated sudden death (ven-
tricular tachycardia or fibrillation).
Statistical analysis. Stepwise multiple logistic regression
analysis and the Cox proportional hazard model (True
Epistat, Richardson, Texas) were used to identify indepen-
dent predictors of hard cardiac events and their incremental
prognostic value (30). Hard event-free survival was evalu-
ated by Kaplan-Meier plots and differences evaluated by
Mantel-Haentzel Chi-square analysis. Continuous data was
expressed as mean 6 standard deviation. Categorical vari-
ables were analyzed by the Chi-square or Fisher’s Exact
Test. Repeated measures analysis of variance (ANOVA)
and multi-way ANOVA were used to compare continuous
data within and among groups. The Bonferroni t-test was
used to identify differences in means. A two-tailed p , 0.05
was considered significant.
RESULTS
Patient data. The mean age was 61 6 13 years. There were
215 men and 135 women. Indications for DASE were the
detection of CAD in 261 patients and myocardial viability
in 89. There was a prior myocardial infarction in 143
patients (41%), hypertension in 236 (67%), diabetes in 141
(40%), hypercholesterolemia in 106 (30%) and cigarette
smoking in 172 (49%). b-adrenergic blocking agents were
used in 72 (21%) patients, ACE inhibitors in 177 (51%),
nitrates in 170 (49%), diuretics in 197 (56%), and digoxin in
155 (44%).
Coronary angiography was performed in a subset of 186
(53%) patients. CAD ($50% luminal diameter stenosis)
was detected in 162 patients (87%) including three vessel
disease in 80 patients, two vessel disease in 57 and single
vessel disease in 25.
Outcome data. There were 134 events (38%) during the
follow-up period including 76 hard events (22%). The 76
hard events consisted of cardiac death in 59 patients,
nonfatal myocardial infarction in 11 and resuscitated sudden
death in 6. The other 58 events consisted of congestive heart
failure in 38 patients and late myocardial revascularization
in 20.
Dobutamine infusion data. The peak dose of dobutamine
was 25 6 9 mg/kg/min. Atropine was used in 193 patients
(55%). The peak systolic blood pressure and heart rates were
139 6 29 mm Hg and 126 6 16 bpm, respectively.
Endpoints for dobutamine-atropine infusion were: target
heart rate in 291 patients (83%), maximum dose in 23 (7%),
severe angina in 12 (3%), nonsustained ventricular tachy-
cardia (6–11 beats) in 11 (3%), hypotension in 6 (2%),
hypertension in 1 (0.3%), vomiting in 3 (1%) and .2 mm of
ST segment elevation in 3 (1%). There were no severe
complications: death, acute myocardial infarction, sustained
ventricular tachycardia or ventricular fibrillation. Frequent
PVCs occurred in 68 patients (19%), nonsustained VT in 28
(8%), ST elevation or depression in 67 (19%) and chest pain
in 73 (21%). Atropine did not increase the incidence of
tachyarrhythmias or side effects. No signs of atropine
intoxication were noted.
Dobutamine echocardiographic data. Resting wall mo-
tion score index was 2.19 6 0.33. The mean resting LVEF
was 30 6 8%. Wall motion score index was 1.86 6 0.41 at
low dose and 2.02 6 0.50 at peak dose. Mean LVEF was
34 6 9% at low dose and 33 6 10% at peak dose.
Dobutamine stress echocardiography revealed sustained im-
provement in all vascular territories in 83 patients (24%),
scar alone in 99 (28%) and inducible ischemia in 168 (48%
with worsening at peak dose only in 60 and biphasic
responses in 104). In patients with inducible ischemia,
abnormalities involved one vascular territory in 77 (left
anterior descending in 49, left circumflex in 7 and right
coronary in 21), two vascular territories in 65 (left anterior
descending and right coronary in 36, left anterior descend-
ing and left circumflex in 18 and left circumflex and right
coronary in 11) and all three vascular territories in 26. Inter
and intraobserver agreement regarding the interpretation of
studies as sustained improvement, scar, biphasic responses
or inducible ischemia at peak dose only were 92% (322/350)
and 96% (48/50), respectively. Inter and intraobserver
agreement regarding resting segmental scores were 88%
(4921/5592) and 92% (716/778), respectively. Inter and
intraobserver agreement regarding segmental responses dur-
ing low and peak dose were 86% (4809/5592) and 91%
(708/778), respectively.
Table 1 compares the patient data according to DASE
findings. Clinical data were similar in all groups except for
lower prevalence of prior myocardial infarction in patients
with sustained improvement. Rest wall motion score index
and ventricular volumes were similar in all groups. The
number of akinetic and dyskinetic segments at rest was
lower in patients with sustained improvement. The number
of vascular territories involved in patients with scar was
similar to the number of vascular territories involved in
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patients with inducible ischemia. Scar was present in one or
more additional vascular territories in 65% (50/77) and 35%
(23/65) with inducible ischemia in one and two vascular
territories, respectively.
The dobutamine-atropine echocardiographic findings in-
fluenced the decision to perform coronary angiography.
Angiography was done in 24% (20/83) of patients with
sustained improvement, 37% (37/99) with scar alone and
77% (129/168, p , 0.001) with inducible ischemia.
In a subset of 186 patients that underwent angiography,
inducible ischemia was predictive of the presence of CAD.
Inducible ischemia occurred in 87% (69/80) of patients with
three vessel disease, 74% (42/57) with two vessel disease,
60% (15/25) with single vessel disease but only 13% with no
disease (3/24, p , 0.01 vs. patients with CAD). Scar alone
did not correlate with the presence or absence of CAD
(34/162 vs. 3/24 without CAD, p 5 NS), whereas sustained
improvement correlated with the absence of CAD (18/24
vs. 2/162 with CAD, p , 0.01).
All patients with sustained improvement or scar only
were treated medically, whereas 51% (78/154) of patients
with inducible ischemia were revascularized within one
month after DASE at the private cardiologist’s discretion
(coronary artery bypass surgery in 67 and percutaneous
transluminal coronary angioplasty in 11). Table 2 compares
patients with inducible ischemia who were medically treated
to those treated with revascularization. The decision to
revascularize these patients was influenced by several factors.
The majority of revascularized patients had lesions in the
proximal or mid left anterior descending artery (p , 0.01 vs.
medical treatment). Angina was more common (p , 0.05).
There were fewer scarred segments, more viability at low
dose and more extensive inducible ischemia in revascular-
ized patients. All other clinical, echocardiographic and
angiographic factors were similar in revascularized and
medically treated patients.
Univariate predictors of adverse outcome. Table 3 com-
pares clinical, resting and dobutamine-atropine echocardio-
graphic data in medically treated patients with hard events,
soft events and no events. Diabetes was more common in
patients with soft events, but all other clinical and resting
echocardiographic data were similar in patients with hard
events, soft events and no events. Dobutamine echocardio-
graphic data were also similar in patients with no events and
soft events but were significantly different in patients with
hard events. Wall motion score was higher and LVEF was
lower in patients with hard events. The number of segments
demonstrating sustained improvement was lower in patients
with hard events. The number of scarred segments was
similar in patients with and without events. Finally, induc-
ible ischemia was more common (p , 0.01) and involved
more segments and vascular territories (p , 0.01) in
patients with hard events than those with soft events or no
events. Left ventricular ejection fraction at peak dose was
lower and decreased from low to peak dose in patients with
hard events.
The incidence of soft events was similar in patients with
sustained improvement (21%, 16/83), scar alone (16%,
16/99) and medically managed patients with inducible
ischemia (12%, 9/90). Early revascularization of patients
with inducible ischemia had a modest effect on the inci-
dence of soft events (22%, 17/78). Heart failure was as
common in medically managed as it was in revascularized
patients (9%, 7/78, vs. 12%, 31/272, p 5 0.69), but late
revascularization was more common in revascularized pa-
tients (13%, 10/78, vs. 4%, 10/272, p , 0.01).
Figure 1 compares hard event rates according to sustained
improvement, scar and inducible ischemia treated with
medical therapy or early revascularization. Hard events were
rare in patients with sustained improvement and similarly
Table 1. Clinical and Echocardiographic Data in DSE Subsets
Sus Imp
All VT
% (N)
(n 5 83)
Scar Only
% (N)
(n 5 99)
Inducible
Ischemia
% (N)
(n 5 168)
Clinical Data
Age (yrs) 57 6 13 62 6 13 65 6 12
Gender (female) 49 (41) 33 (33) 36 (61)
Prior MI 7 (6)* 64 (64) 43 (73)
Diabetes 34 (28) 47 (47) 39 (66)
Smoking 42 (35) 53 (52) 51 (85)
Angina 18 (15) 29 (29) 39 (66)
Heart Failure 63 (52) 59 (58) 51 (86)
b Blocker Rx 10 (8) 27 (27) 22 (37)
ACEI 47 (39) 55 (54) 50 (84)
Diuretic 58 (48) 60 (59) 54 (90)
ECHO Data
Rest WMSI 2.19 6 0.26 2.25 6 0.34 2.15 6 0.34
LV ID 5.8 6 0.8 5.9 6 0.8 5.7 6 0.8
LV ESD 5.3 6 0.9 5.2 6 0.8 5.0 6 0.8
FS (%) 10 6 4 11 6 4 11 6 4
LV EF (%) 29 6 8 30 6 9 31 6 7
LV EDV 208 6 89 214 6 88 191 6 78
LV ESV 150 6 72 151 6 86 133 6 62
LV SV 57 6 25 63 6 28 58 6 22
Ak/Dysk Seg 3.4 6 4.0* 7.2 6 2.4 6.3 6 3.2
DSE
LV EF (%) 2 LD 35 6 10 32 6 9 34 6 8
LV EF (%) 2 PD 40 6 11 34 6 9 28 6 8
EF LD 2 PD 5 6 4 2 6 2 26 6 4
# Vascular Territories
2 DSE
3 VT 0 (0) 6 (6) 15 (26)
2 VT 0 (0) 32 (32) 39 (65)
1 VT 0 (0) 62 (61) 46 (77)
*p , 0.01 vs. scar only and inducible ischemia.
Sus Imp All VT 5 sustained improvement in all vascular territories; MI 5
Myocardial Infarction; Rx 5 therapy; ACEI 5 angiotensin converting enzyme
inhibitor; WMSI 5 wall motion score index; LV 5 left ventricular; ID 5
end-diastolic diameter; ESD 5 end-systolic diameter; FS 5 fractional shortening;
EF 5 ejection fraction; EDV 5 end-diastolic volume; ESV 5 end-systolic volume;
SV 5 stroke volume; Ak/Dysk Seg 5 number of akinetic or dyskinetic segments;
VT 5 number of vascular territories with scar or inducible wall motion abnormalities.
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uncommon in those with scar alone (p 5 0.1). In contrast,
hard events were common (p , 0.0001 vs. nonischemic
responses or scar alone) in medically managed patients with
inducible ischemia. Hard events were as common in med-
ically treated patients with biphasic responses as they were
in patients with worsening at peak dose only, but were more
often (p 5 0.01) fatal in those with biphasic responses
(28/31 vs. 12/23 in those with worsening at peak dose only).
Finally, outcome was better in the subset of patients with
inducible ischemia that were managed with early revascu-
larization and similar to patients with sustained improve-
ment.
The extent of inducible ischemia was also predictive of
hard events in medically treated patients. Inducible wall
motion abnormalities in multiple vascular territories were
more common in patients with hard events (30%, 21/70 vs.
10%, 21/202, p , 0.01) and especially those with fatal
events (33%, 18/54 vs. 11%, 24/218, p , 0.01). Hard events
occurred in 82% (9/11, p , 0.01 vs. no ischemia) of patients
with ischemia in all three vascular territories, 39% (12/31,
p , 0.01 vs. no ischemia and ischemia in three territories)
in two territories, 67% (32/48, p , 0.01 vs. no ischemia) in
one vascular territory and 9% (17/182) with no inducible
ischemia. Fatal events occurred in 73% (8/11, p , 0.01 vs.
no ischemia) of patients with ischemia in all three vascular
territories, 32% (10/31, p , 0.01 vs. no ischemia and
ischemia in three territories) in two territories, 46% (22/48,
p , 0.01 vs. no ischemia) in one territory and 8% (14/182)
with no inducible ischemia.
Multivariate analysis. Table 4 presents the results of
stepwise multiple logistic regression analysis to identify
independent predictors of hard events and the additive
predictive value of resting and DASE. The only indepen-
Table 2. Medical Therapy vs. Revascularization in Patients With Inducible Ischemia
Med RX Revascularization
All
% (N)
(n 5 90)
No Angio
% (N)
(n 5 39)
Angio, no
PTCA/CABG
% (N)
(n 5 51)
PTCA/CABG
% (N)
(n 5 78)
Clinical Data
Age (years) 65 6 12 64 6 13 66 6 11 64 6 13
Gender (female) 39 (35) 41 (16) 37 (19) 41 (26)
Prior MI 56 (50) 46 (18) 63 (32) 55 (23)
Angina 28 (25)† 28 (11)* 27 (14)* 53 (41)
Heart Failure 54 (49) 54 (21) 57 (28) 47 (37)
Beta Blocker 14 (13) 10 (4) 18 (9) 31 (24)
ACE Inhibitor 56 (50) 54 (21) 57 (29) 47 (34)
Diuretic 62 (56) 56 (22) 67 (34) 44 (34)
Hemodynamic Data
Heart Rate (bpm)
Baseline 78 6 13 78 6 12 77 6 14 77 6 14
Peak 131 6 22 132 6 22 131 6 22 125 6 16
Angio Data
CAD (# of vessels) 2.1 6 0.9 2.5 6 0.6
SVD 18 (9) 8 (6)
3V CAD 38 (21) 31 (48)
Prox/mid LAD 77 (39)† 95 (74)
DSE Findings
LVEF (%) 2 Rest 30 6 7 29 6 7 30 6 7 33 6 6
LVEF (%) 2 Low Dose 32 6 7 32 6 7 32 6 7 32 6 7
LVEF (%) 2 Peak Dose 27 6 7 27 6 7 27 6 7 30 6 8
EF Change LD 2 PD 25 6 3 25 6 3 25 6 3 27 6 4
WMSI 2 Rest 2.18 6 0.37 2.12 6 0.37 2.22 6 0.36 2.11 6 0.31
Low Dose WMSI 1.97 6 0.35 1.92 6 0.37 2.01 6 0.33* 1.74 6 0.41
Peak WMSI 2.30 6 0.39 2.20 6 0.42 2.38 6 0.35 2.30 6 0.40
Scarred Segments 5.7 6 2.8 5.1 6 3.0 6.1 6 2.5* 4.2 6 3.1
Sus Imp Segments 1.8 6 2.5 2.0 6 2.9 1.6 6 2.2 2.2 6 3.2
Ischemic Segments 4.2 6 2.2† 3.9 6 2.0† 4.4 6 2.4† 5.9 6 2.7
# Ind WMA 1.6 6 0.7 1.6 6 0.7 1.6 6 0.7 1.8 6 0.8
*p , 0.05 vs. revascularized patients (PTCA/CABG); †p , 0.01 vs. revascularized patients (PTCA/CABG).
bpm 5 beats per minute; Med RX 5 medical therapy; Angio 5 angiography; PTCA/CABG 5 revascularized patients; #
of Ind WMA 5 the number of vascular territories with inducible wall motion abnormalities. See Table 1 for other abbreviations.
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dent predictors of hard cardiac events were inducible isch-
emia and LVEF at peak dose during DASE. All other
clinical and echocardiographic determinants including rest-
ing LVEF, stroke volume, chamber diameter, age and
history of myocardial infarction or heart failure were not
independently predictive of hard events. Stepwise analysis
revealed that: 1) clinical data were modestly predictive of
hard events, 2) resting echocardiography did not improve
the prediction of hard events, but 3) peak dose DASE
markedly improved the accuracy by detecting inducible
ischemia and reduced LVEF at peak dose.
Life table analysis. Figure 2 is a Kaplan-Meier plot of hard
event free survival in the dobutamine-atropine echocardio-
graphic subsets. Patients with sustained improvement did
very well with an 18 month hard event free survival of 95%.
The hard event free survival of patients with scar alone was
similarly good. In contrast, the survival of patients with
inducible ischemia was much worse than patients with
sustained improvement or scar alone. Hard events occurred
throughout the 18 month follow-up period in the subset
with biphasic responses but occurred late in those with
worsening wall motion at peak dose only. Hard event free
survival of patients with inducible ischemia was better in
those treated with revascularization.
Figure 3 is a Kaplan-Meier plot of the survival (number
alive) of the dobutamine-atropine stress echocardiographic
subsets treated medically and with revascularization. Again,
Table 3. Data in Medically Treated Patients With Hard, Soft and No Events
Hard
Events
% (N)
(n 5 70)
Soft
Events
% (N)
(n 5 41)
No Hard or
Soft Events
% (N)
(n 5 161)
Clinical Data
Age (yrs) 63 6 15 62 6 15 60 6 12
Gender (female) 33 (23) 46 (19) 42 (67)
Prior MI 56 (39) 44 (18) 39 (63)
Diabetes 43 (30) 56 (23) 35 (51)†
Smoking 49 (34) 37 (15) 47 (76)
Angina 33 (23) 27 (11) 22 (35)
Heart Failure 65 (46) 63 (26) 54 (87)
b Blocker Rx 19 (13) 17 (7) 17 (28)
ACEI 59 (41) 66 (27) 47 (75)
Heart Rate (bpm) 83 6 13 77 6 14 79 6 15
Resting ECHO Data
Rest WMSI 2.23 6 0.32 2.19 6 0.31 2.20 6 0.34
Mean WT 1.2 6 0.3 1.2 6 0.3 1.1 6 0.3
LVID 5.7 6 0.8 6.1 6 0.9 5.7 6 0.8
LVESD 5.2 6 0.8 5.5 6 0.9 5.1 6 0.8
FS 10 6 4 10 6 4 11 6 4
LVEF 28 6 7 28 6 8 31 6 8
LV EDV 199 6 76 236 6 101 199 6 79
LV ESV 144 6 62 170 6 82 141 6 62
LV SV 55 6 20 66 6 25 58 6 26
Ak/Dyskinetic Seg 6.8 6 3.0 5.6 6 3.3 5.7 6 3.8
DSE Data
LD WMSI 1.99 6 0.34 1.94 6 0.32 1.84 6 0.43
LVEF 2 LD 30 6 8 31 6 8 33 6 9
Sus Imp Seg 2.7 6 3.6*† 5.4 6 5.5 6.6 6 5.8
Scarred Seg 5.5 6 2.9 4.8 6 3.1 4.4 6 3.4
PD WMSI 2.23 6 0.4*† 1.91 6 0.46 1.85 6 0.53
LVEF 2 PD 27 6 9*† 33 6 9 36 6 10
Change EF 2 LD 2 PD 23 6 2*† 2 6 2 3 6 2
Inducible Ischemic Seg 3.3 6 2.8*† 1.1 6 1.9 0.8 6 1.6
DSE Interpretation
Sus Imp All VT 6 (4)*† 39 (16) 39 (63)
Scar 18 (13)*† 39 (16) 44 (70)
Inducible Ischemia 76 (53)*† 22 (9) 17 (28)
# of Ind WMA 1.2 6 1.0*† 0.3 6 0.7 0.3 6 0.7
*p , 0.05 vs. no hard or soft events; † 5 p , 0.05 vs. soft events.
Mean WT 5 average of septal and posterior end-diastolic wall thickness; LD 5 low dose dobutamine; PD 5 peak dose
dobutamine. See Table 1 for other abbreviations.
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patients with sustained improvement and scar alone did
similarly well. The survival of patients with inducible
ischemia was much worse. The survival of patients with
biphasic responses was worse than those with worsening at
peak dose only. The survival of patients with inducible
ischemia was better in those treated with early revascular-
ization.
DISCUSSION
Previous studies. Chronic left ventricular dysfunction and
heart failure are major causes of morbidity and mortality
(1–6). Ischemic cardiomyopathies convey a much worse
prognosis than nonischemic dysfunction (1–9). Coronary
artery disease may cause LVD by infarction, remodeling,
chronic hypoperfusion, and repetitive ischemia and reper-
fusion. Coronary revascularization may convey the greatest
benefit when selectively used in high risk patients (5,6).
Noninvasive techniques may assist in patient manage-
ment by detecting: 1) the mechanism of LVD, 2) viable
myocardium, and 3) the extent and severity of CAD
(16,31). Nuclear cardiologic studies have shown that viable
myocardium in patients with CAD and LVD is predictive
of adverse outcome (8–13). Positron emission tomography
studies have shown that mildly hypoperfused or normally
perfused myocardium with altered metabolism correlates
with adverse outcome in patients with CAD and LVD and
that these same patients have fewer events when revascu-
larized (10–11). PET imaging is limited by its cost and
availability. Iskandrian et al. have reported similar findings
with rest-redistribution Tl-201 scintigraphy (8,9).
Dobutamine-atropine stress echocardiography is an alter-
native test to study patients with LVD and noninvasively
differentiates ischemic from nonischemic cardiomyopathy
by contractile response. Several studies have reported mod-
erate concordance with PET and Tl-201 data (14–20).
Dobutamine-atropine stress echocardiography is very sen-
sitive and moderately specific for CAD in these patients
(17,21,32). Scar can also be differentiated from reversible
dysfunction (14,15,19,20). Wall thinning, increased echo-
genicity and fixed akinesis or dyskinesis identify scar and
fixed dysfunction (26–28). Segments with biphasic re-
sponses commonly recover with revascularization alone with
hypokinetic segments that worsen at peak dose (19,20). In
contrast, sustained improvement at low and peak dose
correlates with fixed dysfunction and differentiates nonisch-
emic from ischemic dysfunction (17,19,20,22).
Dobutamine-atropine stress echocardiography has been
shown to risk stratify patients with acute myocardial infarc-
tion, known or suspected CAD and those considered for
noncardiac surgery (26,33–34). Only one previous study
investigated the value of DASE in LVD (18). Williams et
al. performed DASE in 136 patients with a mean LVEF of
30 6 5%. The remaining 130 were followed for 16 6 8
months. Twenty-two patients were revascularized early and
108 were treated medically. Cardiac events occurred in 24%
(26/108) patients. Events occurred in 43% of patients with
ischemia or viability but only in 8% of patients with scar.
The predictive value was independent of clinical and resting
echocardiographic data. The authors concluded that recur-
rent ischemia in viable myocardium mediated the recurrent
events. The study did not differentiate the relative predictive
values of myocardial viability and ischemia.
The present study. The present study documented the
relative roles of inducible ischemia, improved wall motion
and scar in recurrent cardiac events in patients with LVD.
The study also provided evidence that revascularization may
improve outcome of high risk patients. While it was not
randomized, revascularization was only done in the high risk
subset of patients with inducible ischemia. The extent of
inducible ischemia was greatest in revascularized patients,
but the hard cardiac event rate was reduced. Again, this
study enrolled patients with LVD of various etiologies,
typical of clinical practice. Multivariate analysis showed that
the predictive value of DASE was independent of clinical
data and resting echocardiography.
Dobutamine-atropine stress echocardiography only
predicted hard events. All patients tolerated the infusion
well. Heart failure was not predicted by any clinical,
resting or stress echocardiographic finding. Late revascu-
larization only correlated with the performance of early
revascularization. Left ventricular dimensions were not
predictive of outcome. Hard events were not predicted by
clinical or resting echocardiographic findings. The critical
finding of the study was that hard events were only
predicted by inducible ischemia and reduced LVEF at
peak dose. Sustained improvement alone, especially in all
vascular territories, predicted good outcome. Scar with-
Figure 1. Bar graph of hard cardiac events according to DASE.
Hard events were uncommon in patients with sustained improve-
ment (Sustained Imp) and scar alone but were common (*, p ,
0.01 vs. scar only or sustained improvement) in medically-treated
patients with inducible ischemia. Hard events were uncommon (§,
p , 0.01) in patients with inducible ischemia treated with
revascularization.
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out inducible ischemia also correlated with a low inci-
dence of hard events. In contrast, hard events were
common in patients with inducible ischemia with or
without improvement at low dose (viability). Fatal events
were most common in the subsets with biphasic responses
or inducible ischemia in all vascular territories.
The higher sensitivity of inducible ischemia for coronary
heart disease in the present study likely mediated the
discrepancy in findings of the present study and that of
Williams et al. (18). Inducible ischemia was more common
in the present study (47% vs. 26%, p , 0.05 vs. Williams et
al.). Angiography showed that viability without ischemia
often occurred in patients with CAD in Williams’ study, but
almost always occurred in patients without CAD in the
present study. Both nonischemic cardiomyopathies and
viable but chronically dysfunctional myocardium due to
ischemic heart disease responds to inotropic stimulation, but
only the latter will manifest induced ischemic dysfunction
during stress.
The present study strongly supports the conclusion that
recurrent ischemia in viable, dysfunctional myocardium
mediated recurrent events in these patients. Further evi-
dence is the low incidence of hard events in patients with
inducible ischemia treated with revascularization. These
data compare favorably with the revascularization data of
prior PET studies showing that only patients with meta-
bolically active, dysfunctional myocardium and CAD ben-
efited from revascularization (8–13).
These data imply that patients with LVD should be
evaluated for inducible ischemia. Dobutamine-atropine
stress echocardiography is a safe and accurate method for
identifying inducible ischemia and risk stratifying these
patients (19,20). Selective use of revascularization in high
risk patients identified by DASE improves patient outcome.
Table 4. Computer Directed and Clinically Directed Stepwise Multiple Logistic Regression and Cox Proportion Hazard Analysis of
Determinants of Hard Events in Medically Treated Patients
Hard Events 2 Computer Directed Stepwise Clinical
Univariate Multivariate
Relative Risk
(95% CI)
Cox Hazard
Ratio (95% CI) Steps
Multivariate
x2 P x2 P x2 P
Clinical Data
Age (yrs) 1.83 0.18 NS Step 1 16.1 0.001
Gender (female) 2.08 0.15 NS
Prior MI 5.12 0.02 NS
Diuretic 2.99 0.08 NS
Diabetes 0.85 0.36 NS
Smoking 0.26 0.61 NS
Angina 1.81 0.18 NS
Heart Failure 1.22 0.29 NS
b Blocker Rx 0.05 0.82 NS
ACEI 1.37 0.24 NS
Heart Rate (bpm) 4.90 0.03 NS
Resting ECHO Step 2 1.8 0.35
Rest WMSI 0.71 0.42 NS
LVID 0.38 0.54 NS
FS 2.67 0.10 NS
LVEF 3.83 0.05 NS
LV EDV 0.49 0.49 NS
LV SV 2.16 0.14 NS
Mean WT 2.57 0.11 NS
Ak/Dysk Seg 5.53 0.02 NS
Dobutamine ECHO Step 3 90.3 ,0.0001
PD WMSI 28.53 ,0.0001 NS
LVEF 2 Peak
Dose
35.87 ,0.0001 8.38 0.004 0.95 (0.91–0.98) 0.98 (0.97–0.99)
Change in EF LD
2 PD
60.83 ,0.0001 NS
Scar (# of Seg) 5.49 0.02 NS
Inducible Ischemia 75.35 ,0.0001 75.35 ,0.0001 13.9 (7.2–26.8) 1.5 (1.2–2.0)
Inducible Ischemia
(# of Seg)
56.05 ,0.0001 NS
# of Ind WMA 52.60 ,0.0001 NS
x2 5 Chi-squared value; CI 5 confidence interval; See Tables 1–3 for other abbreviations.
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Limitations. The present study was limited by nonran-
domized surgical management. The decision for revascular-
ization may have been influenced by uncontrollable biases.
Despite these biases, the only difference in medically treated
and revascularized subsets with inducible ischemia was a
higher prevalence of angina and more extensive inducible
ischemia. Thus, revascularized patients may have been at
higher risk and biases likely did not account for the
differences in survival. Another limitation was the limited
coronary angiographic data so the outcome data could not
be compared to angiography. Medical treatment was not
standardized but was uniform and not a determinant of
outcome. We acknowledge that some of the patients with
scar alone or sustained improvement with submaximal peak
heart rates may have demonstrated inducible ischemia at
maximal heart rates. Likely, this would only have had a
minor effect on the data because the number of patients with
scar or sustained improvement and submaximal heart rates
was small.
Conclusions and clinical implications. Dobutamine-
atropine stress echocardiography safely risk stratified pa-
tients with moderate to severe LVD. Results were highly
predictive of nonfatal myocardial infarction and cardiac
death. The major finding of the study was that inducible
ischemia was the major determinant of hard events. Sus-
tained improvement in multiple vascular territories and scar
without ischemia predicted good outcome. Inducible isch-
emia and a low LVEF at peak dose were the only indepen-
dent predictors of hard events. An important corollary was
that biphasic responses were highly predictive of cardiac
deaths. Dobutamine-atropine stress echocardiographic
findings were independent of clinical data and LVEF.
Finally, the nonrandomized data showing that outcome was
better in patients with inducible ischemia treated with
revascularization suggest that outcome may be significantly
improved by selective use of revascularization in these high
risk patients.
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